Posted inClinical Updates
Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Insights from the RHONE-X Extension Trial and Related Evidence
This review synthesizes four-year clinical outcomes of faricimab in diabetic macular edema from the RHONE-X extension trial alongside relevant studies, highlighting durable efficacy, safety, and reduced treatment burden with dual Ang-2/VEGF-A inhibition.
